Dong-Hou Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong-Hou Kim has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Seung-Yong Yoon
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul Korea, Republic of (South)
10 shared publications Kwangmin Cho
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea
4 shared publicationsHeuiran Lee
3 shared publicationsJung Eun Choi
Departments of Anatomy and Cell Biology,1 Microbiology,2 Research Institute for Biomacromolecules, University of Ulsan College of Medicine, Ulsan,3 Department of Medicine, Samsung Medical Center,4 Sungkyunkwan University School of Medicine, Seoul,5 Division of Electron Microscopic Research, Korea Basic Science Institute, Daejeon, South Korea6
3 shared publicationsNa-Young Kim
ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea
3 shared publicationsSeung Yong Yoon
Department of Anatomy and Cell Biology, University of Ulsan College of Medicine, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, South Korea
3 shared publications
Latest Publications
- Open Access
- 29 September 2023
- Published by Springer Nature in Cell & Bioscience
- Vol. 13 (1) , 1-15
Neuronal MHC-I complex is destabilized by amyloid-β and its implications in Alzheimer’s disease
Backgrounds: The expression of major histocompatibility complex I (MHC-I) in neurons has recently been shown to regulate neurite outgrowth and synaptic plasticity. However, its contribution to neurodegenerative diseases such as Alzheimer's disease (AD) remains largely unknown. Methods: In this study, we investigated the relationship between impaired MHC-I-β2M complex and AD in vitro and human AD samples. Interaction between protein was identified by liquid chromatography-tandem mass spectrometry and confirmed by immunoprecipitation. Single-chain trimer of MHC-I-β2M was generated to study the effect of stabilization of MHC-I-β2M complex on NCAM1 signaling. Results: MHC-I is destabilized in the brains of AD patients and neuronal cells treated with oligomeric β-amyloid (Aβ). Specifically, Aβ oligomers disassemble the MHC-I-β2-microglobulin (β2M) complex, leading to reduced interactions with neural cell adhesion molecule 1 (NCAM1), a novel interactor of neuronal MHC-I, and decreased signaling. Inhibition of MHC-I-β2M complex destabilization by non-dissociable MHC-I-β2M-peptide complex restored MHC-I-NCAM1 signaling in neuronal cells. Conclusions: The current study demonstrated that disruption of MHC-1-NCAM1 signaling by Aβ induced disassembly of MHC-I-β2M complex is involved in the pathophysiology of AD. Moreover, our findings suggest modulation of MHC-I stability may be a potential therapeutic target for restoring synaptic function in AD.
- 29 September 2023
- Published by Springer Nature in Cell & Bioscience
- Vol. 13 (1) , 1-15
Open AccessNeuronal MHC-I complex is destabilized by amyloid-β and its implications in Alzheimer’s disease
Backgrounds: The expression of major histocompatibility complex I (MHC-I) in neurons has recently been shown to regulate neurite outgrowth and synaptic plasticity. However, its contribution to neurodegenerative diseases such as Alzheimer's disease (AD) remains largely unknown. Methods: In this study, we investigated the relationship between impaired MHC-I-β2M complex and AD in vitro and human AD samples. Interaction between protein was identified by liquid chromatography-tandem mass spectrometry and confirmed by immunoprecipitation. Single-chain trimer of MHC-I-β2M was generated to study the effect of stabilization of MHC-I-β2M complex on NCAM1 signaling. Results: MHC-I is destabilized in the brains of AD patients and neuronal cells treated with oligomeric β-amyloid (Aβ). Specifically, Aβ oligomers disassemble the MHC-I-β2-microglobulin (β2M) complex, leading to reduced interactions with neural cell adhesion molecule 1 (NCAM1), a novel interactor of neuronal MHC-I, and decreased signaling. Inhibition of MHC-I-β2M complex destabilization by non-dissociable MHC-I-β2M-peptide complex restored MHC-I-NCAM1 signaling in neuronal cells. Conclusions: The current study demonstrated that disruption of MHC-1-NCAM1 signaling by Aβ induced disassembly of MHC-I-β2M complex is involved in the pathophysiology of AD. Moreover, our findings suggest modulation of MHC-I stability may be a potential therapeutic target for restoring synaptic function in AD.
- Open Access
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280–acetylated tau in cell and mouse models
The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer’s disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide 275VQIINK280 of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies, including AD. However, the mechanism that links tau acetylated on lysine 280 (tau-acK280) to subsequent progression to neurodegenerative disease remains unclear. Here, we demonstrate that tau-acK280 is critical for tau propagation processes including secretion, aggregation, and seeding. We developed an antibody, Y01, that specifically targets tau-acK280 and solved the crystal structure of Y01 in complex with an acK280 peptide. The structure confirmed that Y01 directly recognizes acK280 and the surrounding residues. Strikingly, upon interaction with acetylated tau aggregates, Y01 prevented tauopathy progression and increased neuronal viability in neuron cultures and in tau-Tg mice through antibody-mediated neutralization and phagocytosis, respectively. Based on our observations that tau-acK280 is a core species involved in seeding and propagation activities, the Y01 antibody that specifically recognizes acK280 represents a promising therapeutic candidate for AD and other neurodegenerative diseases associated with tauopathy.
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Open AccessMonoclonal antibody Y01 prevents tauopathy progression induced by lysine 280–acetylated tau in cell and mouse models
The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer’s disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide 275VQIINK280 of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies, including AD. However, the mechanism that links tau acetylated on lysine 280 (tau-acK280) to subsequent progression to neurodegenerative disease remains unclear. Here, we demonstrate that tau-acK280 is critical for tau propagation processes including secretion, aggregation, and seeding. We developed an antibody, Y01, that specifically targets tau-acK280 and solved the crystal structure of Y01 in complex with an acK280 peptide. The structure confirmed that Y01 directly recognizes acK280 and the surrounding residues. Strikingly, upon interaction with acetylated tau aggregates, Y01 prevented tauopathy progression and increased neuronal viability in neuron cultures and in tau-Tg mice through antibody-mediated neutralization and phagocytosis, respectively. Based on our observations that tau-acK280 is a core species involved in seeding and propagation activities, the Y01 antibody that specifically recognizes acK280 represents a promising therapeutic candidate for AD and other neurodegenerative diseases associated with tauopathy.
- 28 June 2022
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 133 (12) , 1394-1398
Tau acetylation at K280 regulates tau phosphorylation
Accumulation of hyperphosphorylated tau is a key pathological finding of Alzheimer’s disease. Recently, acetylation of tau is emerging as another key pathogenic modification, especially regarding t...
- 28 June 2022
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 133 (12) , 1394-1398
Tau acetylation at K280 regulates tau phosphorylation
Accumulation of hyperphosphorylated tau is a key pathological finding of Alzheimer’s disease. Recently, acetylation of tau is emerging as another key pathogenic modification, especially regarding t...
- 1 April 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 524 (3) , 764-771
TLQP-21 mediated activation of microglial BV2 cells promotes clearance of extracellular fibril amyloid-β
- 1 April 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 524 (3) , 764-771
TLQP-21 mediated activation of microglial BV2 cells promotes clearance of extracellular fibril amyloid-β
- 1 September 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 129, 182-194
V232M substitution restricts a distinct O-glycosylation of PLD3 and its neuroprotective function
- 1 September 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 129, 182-194
V232M substitution restricts a distinct O-glycosylation of PLD3 and its neuroprotective function
- 1 March 2019
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 95, 13-24
Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer's disease
- 1 March 2019
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 95, 13-24
Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer's disease
- Open Access
- 21 January 2017
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 9 (1) , 1-14
Sorting nexin-4 regulates β-amyloid production by modulating β-site-activating cleavage enzyme-1
Amyloid precursor protein (APP) is cleaved by β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) to produce β-amyloid (Aβ), a critical pathogenic peptide in Alzheimer’s disease (AD). Aβ generation can be affected by the intracellular trafficking of APP or its related secretases, which is thus important to understanding its pathological alterations. Although sorting nexin (SNX) family proteins regulate this trafficking, the relevance and role of sorting nexin-4 (SNX4) regarding AD has not been studied yet. In this study, human brain tissue and APP/PS1 mouse brain tissue were used to check the disease relevance of SNX4. To investigate the role of SNX4 in AD pathogenesis, several experiments were done, such as coimmunoprecipitation, Western blotting, immunohistochemistry, and gradient fractionation. We found that SNX4 protein levels changed in the brains of patients with AD and of AD model mice. Overexpression of SNX4 significantly increased the levels of BACE1 and Aβ. Downregulation of SNX4 had the opposite effect. SNX4 interacts with BACE1 and prevents BACE1 trafficking to the lysosomal degradation system, resulting in an increased half-life of BACE1 and increased production of Aβ. We show that SNX4 regulates BACE1 trafficking. Our findings suggest novel therapeutic implications of modulating SNX4 to regulate BACE1-mediated β-processing of APP and subsequent Aβ generation.
- 21 January 2017
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 9 (1) , 1-14
Open AccessSorting nexin-4 regulates β-amyloid production by modulating β-site-activating cleavage enzyme-1
Amyloid precursor protein (APP) is cleaved by β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) to produce β-amyloid (Aβ), a critical pathogenic peptide in Alzheimer’s disease (AD). Aβ generation can be affected by the intracellular trafficking of APP or its related secretases, which is thus important to understanding its pathological alterations. Although sorting nexin (SNX) family proteins regulate this trafficking, the relevance and role of sorting nexin-4 (SNX4) regarding AD has not been studied yet. In this study, human brain tissue and APP/PS1 mouse brain tissue were used to check the disease relevance of SNX4. To investigate the role of SNX4 in AD pathogenesis, several experiments were done, such as coimmunoprecipitation, Western blotting, immunohistochemistry, and gradient fractionation. We found that SNX4 protein levels changed in the brains of patients with AD and of AD model mice. Overexpression of SNX4 significantly increased the levels of BACE1 and Aβ. Downregulation of SNX4 had the opposite effect. SNX4 interacts with BACE1 and prevents BACE1 trafficking to the lysosomal degradation system, resulting in an increased half-life of BACE1 and increased production of Aβ. We show that SNX4 regulates BACE1 trafficking. Our findings suggest novel therapeutic implications of modulating SNX4 to regulate BACE1-mediated β-processing of APP and subsequent Aβ generation.
- 1 October 2016
- Published by Elsevier in Brain Research
- Vol. 1649, 201-209
Alzheimer's disease genes and autophagy
- 1 October 2016
- Published by Elsevier in Brain Research
- Vol. 1649, 201-209
Alzheimer's disease genes and autophagy
- Open Access
- 31 July 2016
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 49 (7) , 376-381
c-Jun N-terminal Kinase (JNK) induces phosphorylation of amyloid precursor protein (APP) at Thr668, in okadaic acid-induced neurodegeneration
Several lines of evidence have revealed that phosphorylation of amyloid precursor protein (APP) at Thr668 is involved in the pathogenesis of Alzheimer's disease (AD). Okadaic acid (OA), a protein phosphatase-2A inhibitor, has been used in AD research models to increase tau phosphorylation and induce neuronal death. We previously showed that OA increased levels of APP and induced accumulation of APP in axonal swellings. In this study, we found that in OA-treated neurons, phosphorylation of APP at Thr668 increased and accumulated in axonal swellings by c-jun N-terminal kinase (JNK), and not by Cdk5 or ERK/MAPK. These results suggest that JNK may be one of therapeutic targets for the treatment of AD. [BMB Reports 2016; 49(7): 376-381].
- 31 July 2016
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 49 (7) , 376-381
Open Accessc-Jun N-terminal Kinase (JNK) induces phosphorylation of amyloid precursor protein (APP) at Thr668, in okadaic acid-induced neurodegeneration
Several lines of evidence have revealed that phosphorylation of amyloid precursor protein (APP) at Thr668 is involved in the pathogenesis of Alzheimer's disease (AD). Okadaic acid (OA), a protein phosphatase-2A inhibitor, has been used in AD research models to increase tau phosphorylation and induce neuronal death. We previously showed that OA increased levels of APP and induced accumulation of APP in axonal swellings. In this study, we found that in OA-treated neurons, phosphorylation of APP at Thr668 increased and accumulated in axonal swellings by c-jun N-terminal kinase (JNK), and not by Cdk5 or ERK/MAPK. These results suggest that JNK may be one of therapeutic targets for the treatment of AD. [BMB Reports 2016; 49(7): 376-381].
- Top Cited PapersOpen Access
- 12 July 2016
- Published by Springer Nature in Molecular Psychiatry
- Vol. 22 (11) , 1576-1584
Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects
Autism spectrum disorders (ASDs) are neurodevelopmental disorders caused by various genetic and environmental factors that result in synaptic abnormalities. ASD development is suggested to involve microglia, which have a role in synaptic refinement during development. Autophagy and related pathways are also suggested to be involved in ASDs. However, the precise roles of microglial autophagy in synapses and ASDs are unknown. Here, we show that microglial autophagy is involved in synaptic refinement and neurobehavior regulation. We found that deletion of atg7, which is vital for autophagy, from myeloid cell-specific lysozyme M-Cre mice resulted in social behavioral defects and repetitive behaviors, characteristic features of ASDs. These mice also had increases in dendritic spines and synaptic markers and altered connectivity between brain regions, indicating defects in synaptic refinement. Synaptosome degradation was impaired in atg7-deficient microglia and immature dendritic filopodia were increased in neurons co-cultured with atg7-deficient microglia. To our knowledge, our results are the first to show the role of microglial autophagy in the regulation of the synapse and neurobehaviors. We anticipate our results to be a starting point for more comprehensive studies of microglial autophagy in ASDs and the development of putative therapeutics.
- 12 July 2016
- Published by Springer Nature in Molecular Psychiatry
- Vol. 22 (11) , 1576-1584
Top Cited PapersOpen AccessDeficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects
Autism spectrum disorders (ASDs) are neurodevelopmental disorders caused by various genetic and environmental factors that result in synaptic abnormalities. ASD development is suggested to involve microglia, which have a role in synaptic refinement during development. Autophagy and related pathways are also suggested to be involved in ASDs. However, the precise roles of microglial autophagy in synapses and ASDs are unknown. Here, we show that microglial autophagy is involved in synaptic refinement and neurobehavior regulation. We found that deletion of atg7, which is vital for autophagy, from myeloid cell-specific lysozyme M-Cre mice resulted in social behavioral defects and repetitive behaviors, characteristic features of ASDs. These mice also had increases in dendritic spines and synaptic markers and altered connectivity between brain regions, indicating defects in synaptic refinement. Synaptosome degradation was impaired in atg7-deficient microglia and immature dendritic filopodia were increased in neurons co-cultured with atg7-deficient microglia. To our knowledge, our results are the first to show the role of microglial autophagy in the regulation of the synapse and neurobehaviors. We anticipate our results to be a starting point for more comprehensive studies of microglial autophagy in ASDs and the development of putative therapeutics.